UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 25, 2011
| AMERICAN BIO MEDICA CORPORATION |
| (Exact name of registrant as specified in its charter) |
| New York | | 0-28666 | | 14-1702188 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification Number) |
122 Smith Road, Kinderhook, NY 12106
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 25, 2011, American Bio Medica Corporation (“ABMC”) received letters of resignation from its EVP of Finance and Chief Financial Officer Stefan Parker and its EVP of Operations Douglas Casterlin. ABMC’s Chief Executive Officer Stan Cipkowski will assume the position of interim Chief Financial Officer while ABMC seeks a replacement for Mr. Parker. ABMC does not plan to fill Mr. Casterlin’s position at this time; rather Mr. Casterlin’s responsibilities will be absorbed by other ABMC employees where appropriate.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | AMERICAN BIO MEDICA CORPORATION (Registrant) |
| | |
| Dated: March 31, 2011 | By: | /s/ Melissa A. Waterhouse |
| | | Melissa A. Waterhouse |
| | | Vice President & Chief Compliance Officer |
| | | Corporate Secretary |
